Abstract

Arsenic enhances the carcinogenicity of ultraviolet radiation (UVR). However, the mechanisms of arsenic-driven oncogenesis are not well understood. Here, we utilize experimental systems to investigate the carcinogenic and mutagenic properties of co-exposure to arsenic and UVR. In vitro and in vivo exposures indicate that, by itself, arsenic is not mutagenic. However, in combination with UVR, arsenic exposure has a synergistic effect leading to an accelerated mouse skin carcinogenesis and to more than 2-fold enrichment of UVR mutational burden. Notably, mutational signature ID13, previously found only in UVR-associated human skin cancers, is observed exclusively in mouse skin tumors and cell lines jointly exposed to arsenic and UVR. This signature was not observed in any model system exposed purely to arsenic or purely to UVR, making ID13, to the best of our knowledge, the first co-exposure signature to be reported using controlled experimental conditions. Analysis of existing skin cancer genomics data reveals that only a subset of cancers harbor ID13 and these exhibit an elevated UVR mutagenesis. Our results report a unique mutational signature caused by a co-exposure to two environmental carcinogens and provide comprehensive evidence that arsenic is a potent co-mutagen and co-carcinogen of UVR.

Arsenic and ultraviolet radiation (UVR) are potent carcinogens. This study shows that a co-exposure to both arsenic and UVR leads to an accelerated mouse skin carcinogenesis due to an enhanced accumulation of UVR-associated somatic mutations.

Details

Title
Arsenic is a potent co-mutagen of ultraviolet light
Author
Speer, Rachel M. 1 ; Nandi, Shuvro P. 2   VIAFID ORCID Logo  ; Cooper, Karen L. 1 ; Zhou, Xixi 1 ; Yu, Hui 3 ; Guo, Yan 3 ; Hudson, Laurie G. 1 ; Alexandrov, Ludmil B. 2   VIAFID ORCID Logo  ; Liu, Ke Jian 4   VIAFID ORCID Logo 

 University of New Mexico, Department of Pharmaceutical Sciences, College of Pharmacy, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502) 
 Department of Cellular and Molecular Medicine, UC San Diego, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Moores Cancer Center, UC San Diego, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242); Department of Bioengineering, UC San Diego, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242) 
 Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA (GRID:grid.419791.3) (ISNI:0000 0000 9902 6374) 
 University of New Mexico, Department of Pharmaceutical Sciences, College of Pharmacy, Albuquerque, USA (GRID:grid.266832.b) (ISNI:0000 0001 2188 8502); Stony Brook Cancer Center, Stony Brook University, Stony Brook, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681); Stony Brook University School of Medicine, Department of Pathology, Stony Brook, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681) 
Pages
1273
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2902590517
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.